Abstract
Background
Pleomorphic lobular carcinoma in situ (PLCIS) is an uncommon high-grade in situ lesion that shares morphologic features of both classic lobular and ductal carcinoma in situ. Data on the natural history of pure PLCIS are limited, and no evidence-based consensus guidelines for management exist.
Methods
From our prospectively maintained institutional pathology and breast surgery databases, we identified all patients with a diagnosis of PLCIS on core needle biopsy (CNB) or excisional biopsy from 2004 to 2017. Patient, tumor, treatment, and outcome data were abstracted to analyze upstage rates and treatment outcomes.
Results
We identified 18 patients with pure PLCIS: 15 diagnosed on CNB, 2 diagnosed at operation for atypia on CNB, and 1 diagnosed after excisional biopsy without preceding CNB. Of the 15 patients with PLCIS on CNB, 3 (20%) were upgraded to invasive cancer on surgical excision. Overall, 7 patients were treated with mastectomy (all margin-negative) and 11 with lumpectomy (one with a focally positive margin). Eight patients received adjuvant therapy: six endocrine therapy, one radiation therapy, and one received both. Among patients with a final diagnosis of PLCIS, two ipsilateral recurrences were observed at follow-up: one invasive lobular carcinoma at 87 months and one PLCIS at 16 months postoperatively.
Conclusion
PLCIS on CNB mandates surgical resection as 20% of patients may be upgraded to invasive cancer, and outcomes following pathologic margin-negative surgical resection were excellent with only one invasive recurrence observed. Larger-scale investigation with longer follow-up is needed to define a role for adjuvant therapy and to develop evidence-based treatment guidelines.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Frost AR, Tsangaris TN, Silverberg SG. Pleomorphic lobular carcinoma in situ. Pathol Case Rev. 1996;1:27–31.
Gomes DS, Porto SS, Rocha RM, Gobbi H. Usefulness and limitations of E-cadherin and beta-catenin in the classification of breast carcinomas in situ with mixed pattern. Diagn Pathol. 2013;8:114.
Masannat YA, Baines SK, Pinder SE, Purushotham AD. Challenges in the management of pleomorphic lobular carcinoma in situ of the breast. Breast. 2013;22(2):194–6.
NCCN Clinical Practice Guidelines in Oncology. Breast Cancer 2018. Accessed 30 Mar 2018; Available at www.NCCN.org.
Pieri AJ, Harvey J, Bundred N. Pleomorphic lobular carcinoma in situ of the breast: can the evidence guide practice? World J Clin Oncol. 2014;5:546–53.
Blair SL, Emerson DK, Kulkarni S, Hwang ES, Malcarne V, Ollila DW. Breast surgeon’s survey: no consensus for surgical treatment of pleomorphic lobular carcinoma in situ. Breast J. 2013;19:116–8.
Blair SL, Thompson K, Rococco J, Malcarne V, Beitsch PD, Ollila DW. Attaining negative margins in breast-conservation operations: is there a consensus among breast surgeons? J Am Coll Surg. 2009;209:608–13.
Sullivan ME, Khan SA, Sullu Y, Schiller C, Susnik B. Lobular carcinoma in situ variants in breast cores: potential for misdiagnosis, upgrade rates at surgical excision, and practical implications. Arch Pathol Lab Med. 2010;134:1024–8.
Khoury T, Karabakhtsian RG, Mattson D, et al. Pleomorphic lobular carcinoma in situ of the breast: clinicopathological review of 47 cases. Histopathology. 2014;64:981–93.
Chen YY, Hwang ES, Roy R, et al. Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast. Am J Surg Pathol. 2009;33: 1683–94.
Wazir U, Wazir A, Wells C, Mokbel K. Pleomorphic lobular carcinoma in situ: current evidence and a systemic review. Oncol Lett. 2016;12:4863–4868.
De Brot M, Koslow MS, Muhsen S, et al. Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review. Breast Cancer Res Treat. 2017;165:411–420.
Downs-Kelly E, Bell D, Perkins GH, Sneige N, Middleton LP. Clinical implications of margin involvement by pleomorphic lobular carcinoma in situ. Arch Pathol Lab Med. 2011;135:737–43.
Guo T, Wang Y, Shapiro N, Fineberg S. Pleomorphic lobular carcinoma in situ diagnosed by breast core biopsy: clinicopathologic features and correlation with subsequent excision. Clin Breast Cancer. 2017. https://doi.org/10.1016/j.clbc.2017.10.004.
Fasola CE, Chen JJ, Jensen KC, Allison KH, Horst KC. Characteristics and clinical outcomes of pleomorphic lobular carcinoma in situ of the breast. Breast J. 2018;4:66–69.
Flanagan MR, Rendi MH, Calhoun KE, Anderson BO, Javid SH. Pleomorphic lobular carcinoma in situ: radiologic-pathologic features and clinical management. Ann Surg Oncol. 2015;22:4263–9.
Gradishar WJ, Anderson BO, Balassanian R, et al. Breast cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16:310–320.
Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353:1993–2000.
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90:1371–88.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
The authors have no relevant conflicts of interest to disclose.
Rights and permissions
About this article
Cite this article
Desai, A.A., Jimenez, R.E., Hoskin, T.L. et al. Treatment Outcomes for Pleomorphic Lobular Carcinoma In Situ of the Breast. Ann Surg Oncol 25, 3064–3068 (2018). https://doi.org/10.1245/s10434-018-6591-6
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-018-6591-6